CUE-302

CUE-302 is a preclinical-stage biologic candidate developed by Cue Biopharma for the treatment of autoimmune diseases. It is part of the company's Immuno-STAT (Selective Targeting and Alteration of T cells) platform, which utilizes fusion proteins to modulate specific T cell populations. CUE-302 is designed to target PD-L1 (Programmed death-ligand 1) along with an undisclosed autoimmune-specific target. The mechanism of action involves leveraging PD-L1-associated immune regulation to selectively suppress or regulate autoreactive T cells, thereby addressing the underlying cause of autoimmune pathology without broad immunosuppression.